Nordic and Astorg to buy New Mountain Capital’s Cytel in $1bn deal

Benefiting from existing trends that are accelerating through the global health crisis, Cytel is riding the tailwinds of pharma R&D growth and the push to make R&D spend more efficient. 

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this